Top

Published in:

01-05-2014

Atrial fibrillation in heart failure: drug therapies for rate and rhythm control

Authors: Rafik Tadros, Paul Khairy, Jean L. Rouleau, Mario Talajic, Peter G. Guerra, Denis Roy

Published in: Heart Failure Reviews | Issue 3/2014

Abstract

Pharmacological treatment of atrial fibrillation in the context of heart failure poses numerous challenges. Management decisions are limited by contraindications to several drugs and the paucity of robust clinical trials that provide evidence-based guidance. This review proposes a structured action plan for managing atrial fibrillation coexisting with heart failure that considers published clinical guidelines and integrates recent data derived from substudies of randomized trials, including the atrial fibrillation and congestive heart failure (AF-CHF) trial. Areas of uncertainty, such as target heart rates in atrial fibrillation and upstream therapies, are also discussed.

Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S (2012) Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. doi:10.1111/j.1540-8159.2012.03513.x

Freudenberger RS, Wilson AC, Kostis JB (2007) Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol 100(2):247–252. doi:10.1016/j.amjcard.2007.02.101 PubMedCrossRef

Hagens VE, Crijns HJ, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M et al (2005) Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 149(6):1106–1111. doi:10.1016/j.ahj.2004.11.030 PubMedCrossRef

Roy D, Talajic M, Nattel S, Wyse DG, Dorian P et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358(25):2667–2677. doi:10.1056/NEJMoa0708789 PubMedCrossRef

Kong MH, Shaw LK, O’Connor C, Califf RM, Blazing MA et al (2010) Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure? Ann Noninvasive Electrocardiol 15(3):209–217. doi:10.1111/j.1542-474X.2010.00365.x PubMedCrossRef

McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J et al (2012) The 2012 Canadian cardiovascular society heart failure management guidelines update: focus on acute and chronic heart failure Can J Cardiol. doi:10.1016/j.cjca.2012.10.007

Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS et al (2009) 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American college of cardiology foundation/American heart association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14):e391–479. doi:10.1161/CIRCULATIONAHA.109.192065 PubMedCrossRef

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J 33(14):1787–1847. doi:10.1093/eurheartj/ehs104 PubMedCrossRef

Henrard V, Ducharme A, Khairy P, Gisbert A, Roy D et al (2011) Cardiac remodeling with rhythm versus rate control strategies for atrial fibrillation in patients with heart failure: Insights from the AF-CHF echocardiographic sub-study. Int J Cardiol. doi:10.1016/j.ijcard.2011.08.077

10.

Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T et al (2009) A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 95(11):924–930. doi:10.1136/hrt.2008.158931 PubMedCrossRef

11.

Suman-Horduna I, Roy D, Frasure-Smith N, Talajic M, Lesperance F et al (2012) Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol. doi:10.1016/j.jacc.2012.10.031

12.

Poulin F, Khairy P, Levesque S, Roy D, Talajic M et al (2011) Atrial fibrillation and congestive heart failure: a cost analysis of rate versus rhythm control strategies. J Am Coll Cardiol 57 (14s1):E1183

13.

Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R et al (1998) Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98(23):2574–2579PubMedCrossRef

14.

Pedersen OD, Bagger H, Keller N, Marchant B, Kober L et al (2001) Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation 104(3):292–296PubMedCrossRef

15.

Talajic M, Khairy P, Levesque S, Connolly SJ, Dorian P et al (2010) Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol 55(17):1796–1802. doi:10.1016/j.jacc.2010.01.023 PubMedCrossRef

16.

Frasure-Smith N, Lesperance F, Talajic M, Khairy P, Dorian P et al (2012) Anxiety sensitivity moderates prognostic importance of rhythm-control versus rate-control strategies in patients with atrial fibrillation and congestive heart failure: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail 5(3):322–330. doi:10.1161/CIRCHEARTFAILURE.111.964122 PubMedCrossRef

17.

Swedberg K, Komajda M, Bohm M, Borer JS, Ford I et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885. doi:10.1016/S0140-6736(10)61198-1 PubMedCrossRef

18.

Bohm M, Swedberg K, Komajda M, Borer JS, Ford I et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744):886–894. doi:10.1016/S0140-6736(10)61259-7 PubMedCrossRef

19.

Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG et al (2010) Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362(15):1363–1373. doi:10.1056/NEJMoa1001337 PubMedCrossRef

20.

Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S et al (2012) Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: assessment of reduction in mortality and morbidity) program. J Am Coll Cardiol 59(20):1785–1795. doi:10.1016/j.jacc.2011.12.044 PubMedCrossRef

21.

Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F, Hillege HL et al (2006) A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival. Int J Cardiol 109(1):95–100. doi:10.1016/j.ijcard.2005.05.054 PubMedCrossRef

22.

Silvet H, Hawkins LA, Jacobson AK (2012) Heart Rate Control in Patients With Chronic Atrial Fibrillation and Heart Failure. Congest Heart Fail. doi:10.1111/j.1751-7133.2012.00309.x

23.

Andrade JG, Roy D, Wyse DG, Tardif JC, Talajic M et al (2012) Baseline heart rate and adverse outcomes in patients with atrial fibrillation: a combined AFFIRM and AF-CHF sub-study. Can J Cardiol 28(5):S271–S272CrossRef

24.

Camm AJ, Lip GY, De Caterina R, Savelieva I (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33(21):2719–2747. doi:10.1093/eurheartj/ehs253 PubMedCrossRef

25.

Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB et al (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123(10):e269–367. doi:10.1161/CIR.0b013e318214876d PubMedCrossRef

26.

Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M et al (2011) Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365(24):2268–2276. doi:10.1056/NEJMoa1109867 PubMedCrossRef

27.

Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S et al (2008) Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358(25):2678–2687. doi:10.1056/NEJMoa0800456 PubMedCrossRef

28.

Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN (1999) Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 33(2):304–310PubMedCrossRef

29.

(1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353(9169):2001–2007

30.

(1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353(9146):9–13

31.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US. Carvedilol Heart Failure Study Group. N Engl J Med 334(21):1349–1355. doi:10.1056/NEJM199605233342101 PubMedCrossRef

32.

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651–1658. doi:10.1056/NEJM200105313442201 PubMedCrossRef

33.

Gillis AM, Verma A, Talajic M, Nattel S, Dorian P (2011) Canadian cardiovascular society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol 27(1):47–59. doi:10.1016/j.cjca.2010.11.001 PubMedCrossRef

34.

Vittorio TJ, Zolty R, Kasper ME, Khandwalla RM, Hirsh DS et al (2008) Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. J Cardiovasc Pharmacol Ther 13(1):51–57. doi:10.1177/1074248407312629 PubMedCrossRef

35.

Rau T, Dungen HD, Edelmann F, Waagstein F, Lainscak M et al (2012) Impact of the beta1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther 92(1):21–28. doi:10.1038/clpt.2012.18 PubMedCrossRef

36.

Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC et al (2001) Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 142(3):498–501. doi:10.1067/mhj.2001.117318 PubMedCrossRef

37.

Fung JW, Chan SK, Yeung LY, Sanderson JE (2002) Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. Eur J Heart Fail 4(4):489–494PubMedCrossRef

38.

Stankovic I, Neskovic AN, Putnikovic B, Apostolovic S, Lainscak M et al (2012) Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure—insight from the cardiac insufficiency bisoprolol study in elderly. Int J Cardiol 161(3):160–165. doi:10.1016/j.ijcard.2012.06.004 PubMedCrossRef

39.

Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A et al (2001) Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103(10):1428–1433PubMedCrossRef

40.

Mulder BA, van Veldhuisen DJ, Crijns HJ, Bohm M, Cohen-Solal A et al (2012) Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail 14(10):1171–1178. doi:10.1093/eurjhf/hfs100 PubMedCrossRef

41.

van Veldhuisen DJ, Aass H, El Allaf D, Dunselman PH, Gullestad L et al (2006) Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail 8(5):539–546. doi:10.1016/j.ejheart.2006.01.015 PubMedCrossRef

42.

Withering W (1785) An account of the foxglove, and some of its medical uses with practical remarks on dropsy and other diseases. Birmingham

43.

(1997) The effect of digoxin on mortality and morbidity in patients with heart failure. The digitalis investigation group. N Engl J Med 336(8):525–533. doi:10.1056/NEJM199702203360801

44.

Alboni P, Shantha N, Filippi L, Pirani R, Preziosi S et al (1984) Clinical effects of digoxin on sinus node and atrioventricular node function after pharmacologic autonomic blockade. Am Heart J 108(5):1255–1261PubMedCrossRef

45.

Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I et al (2003) Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42(11):1944–1951PubMedCrossRef

46.

Fauchier L, Grimard C, Pierre B, Nonin E, Gorin L et al (2009) Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 103(2):248–254. doi:10.1016/j.amjcard.2008.09.064 PubMedCrossRef

47.

Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL et al (2012) Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J. doi:10.1093/eurheartj/ehs348

48.

(1997) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6,500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 350(9089):1417–1424

49.

Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD et al (1995) Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 333(2):77–82. doi:10.1056/NEJM199507133330201 PubMedCrossRef

50.

Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ et al (2000) Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. N Engl J Med 342(13):913–920. doi:10.1056/NEJM200003303421302 PubMedCrossRef

51.

Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B et al (2005) Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352(18):1861–1872. doi:10.1056/NEJMoa041705 PubMedCrossRef

52.

Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G et al (2003) Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 41(2):255–262PubMedCrossRef

53.

Cadrin-Tourigny J, Wyse DG, Roy D, Levesque S, Talajic M et al (2011) Amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a combined AFFIRM and AF-CHF analysis. Heart Rhythm 8(5):888

54.

Cotter G, Blatt A, Kaluski E, Metzkor-Cotter E, Koren M et al (1999) Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. Eur Heart J 20(24):1833–1842. doi:10.1053/euhj.1999.1747 PubMedCrossRef

55.

Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E et al (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341(12):857–865. doi:10.1056/NEJM199909163411201 PubMedCrossRef

56.

Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ et al (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet 348(9019):7–12PubMedCrossRef

57.

Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S et al (1999) Prevention of implantable-defibrillator shocks by treatment with sotalol. d, l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 340(24):1855–1862. doi:10.1056/NEJM199906173402402 PubMedCrossRef

58.

Nieuwlaat R, Eurlings LW, Cleland JG, Cobbe SM, Vardas PE et al (2009) Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 53(18):1690–1698. doi:10.1016/j.jacc.2009.01.055 PubMedCrossRef

59.

Boldt LH, Rolf S, Huemer M, Parwani AS, Luft FC et al (2008) Optimal heart failure therapy and successful cardioversion in heart failure patients with atrial fibrillation. Am Heart J 155(5):890–895. doi:10.1016/j.ahj.2007.12.015 PubMedCrossRef

60.

Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL et al (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47(10):1997–2004. doi:10.1016/j.jacc.2006.01.060 PubMedCrossRef

61.

Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE et al (2010) Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55(21):2299–2307. doi:10.1016/j.jacc.2010.01.043 PubMedCrossRef

62.

Li D, Shinagawa K, Pang L, Leung TK, Cardin S et al (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104(21):2608–2614PubMedCrossRef

63.

Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L et al (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360(16):1606–1617. doi:10.1056/NEJMoa0805710 PubMedCrossRef

64.

Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M et al (2011) Irbesartan in patients with atrial fibrillation. N Engl J Med 364(10):928–938. doi:10.1056/NEJMoa1008816 PubMedCrossRef

65.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341(10):709–717. doi:10.1056/NEJM199909023411001 PubMedCrossRef

66.

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. doi:10.1056/NEJMoa1009492 PubMedCrossRef

67.

Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ et al (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study. J Am Coll Cardiol 59(18):1598–1603. doi:10.1016/j.jacc.2011.11.063 PubMedCrossRef

68.

Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C et al (2010) Effect of combined spironolactone-beta-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol 106(11):1609–1614. doi:10.1016/j.amjcard.2010.07.037 PubMedCrossRef

69.

Williams RS, deLemos JA, Dimas V, Reisch J, Hill JA et al (2011) Effect of spironolactone on patients with atrial fibrillation and structural heart disease. Clin Cardiol 34(7):415–419. doi:10.1002/clc.20914 PubMedCentralPubMedCrossRef

70.

O’Meara E, Khairy P, Blanchet MC, de Denus S, Pedersen OD et al (2012) Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail 5(5):586–593. doi:10.1161/CIRCHEARTFAILURE.111.965160 PubMedCrossRef

71.

Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG et al (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372(9645):1231–1239. doi:10.1016/S0140-6736(08)61240-4 PubMedCrossRef

72.

Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG et al (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357(22):2248–2261. doi:10.1056/NEJMoa0706201 PubMedCrossRef

73.

Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG et al (2009) Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 30(19):2327–2336. doi:10.1093/eurheartj/ehp357 PubMedCrossRef

74.

Fang WT, Li HJ, Zhang H, Jiang S (2012) The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol 74(5):744–756. doi:10.1111/j.1365-2125.2012.04258.x PubMedCentralPubMedCrossRef

75.

Koutbi L, Roy D, Talajic M, Blondeau L, Franceschi F et al (2012) Statins and atrial fibrillation in patients with left ventricular dysfunction: insights from the AF-CHF trial. Int J Cardiol. doi:10.1016/j.ijcard.2012.09.033

76.

Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG et al (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372(9645):1223–1230. doi:10.1016/S0140-6736(08)61239-8 PubMedCrossRef

77.

Wu JH, Lemaitre RN, King IB, Song X, Sacks FM et al (2012) Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. Circulation 125(9):1084–1093. doi:10.1161/CIRCULATIONAHA.111.062653 PubMedCentralPubMedCrossRef

78.

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P et al (2012) Fish oil and postoperative atrial fibrillation: the omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. JAMA 308(19):2001–2011. doi:10.1001/jama.2012.28733 PubMedCentralPubMedCrossRef

79.

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N et al (2012) Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol. doi:10.1016/j.jacc.2012.11.021

80.

Mozaffarian D, Wu JH (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58(20):2047–2067. doi:10.1016/j.jacc.2011.06.063 PubMedCrossRef

81.

Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP (2009) Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 120(23):2315–2321. doi:10.1161/CIRCULATIONAHA.109.852657 PubMedCrossRef

82.

Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML et al (2005) N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 45(10):1723–1728. doi:10.1016/j.jacc.2005.02.079 PubMedCrossRef

83.

Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM (2010) Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 304(21):2363–2372. doi:10.1001/jama.2010.1735 PubMedCrossRef

84.

Tremblay-Gravel M, White M, Roy D, Leduc H, Wyse DG et al (2012) Blood pressure and atrial fibrillation: a combined AF-CHF and AFFIRM analysis. Can J Cardiol 28(5):S290CrossRef

85.

Dyrda K, Roy D, Leduc H, Talajic M, Macle L et al (2012) Adapting treatment strategies in patients with atrial fibrillation and congestive heart failure: an AF-CHF substudy. Heart Rhythm 9(5):S264

86.

Smit MD, Van Veldhuisen DJ, Van Gelder IC (2010) Guidelines for atrial fibrillation in heart failure need to be clarified. J Am Coll Cardiol 55 (2):167; author reply 168–169. doi:10.1016/j.jacc.2009.05.081

Title: Atrial fibrillation in heart failure: drug therapies for rate and rhythm control
Authors: Rafik Tadros
Paul Khairy
Jean L. Rouleau
Mario Talajic
Peter G. Guerra
Denis Roy
Publication date: 01-05-2014
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 3/2014
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-013-9395-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Atrial fibrillation in heart failure: drug therapies for rate and rhythm control

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Obesity as a risk factor for poor neurocognitive outcomes in older adults with heart failure

Combined management of atrial fibrillation and heart failure: case studies

Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases

Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation

New perspectives of nitric oxide donors in cardiac arrest and cardiopulmonary resuscitation treatment

Clinical use of novel biomarkers in heart failure: towards personalized medicine

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page